This randomized, split-body clinical trial aims to evaluate the efficacy, safety, and participant satisfaction of the Mesolipo® protocol for the treatment of localized adiposity. Participants will receive the Mesolipo® intervention on one side of the body and an active comparator on the contralateral side. Outcomes will be assessed through standardized clinical, photographic, ultrasonographic, and patient-reported measures over a 90-day follow-up period to determine treatment effectiveness and safety.
Inclusion Criteria:
Exclusion Criteria:
Participants and outcome assessors will be blinded to the intervention assigned to each side of the body. The professional responsible for preparing or administering the interventions will not be blinded. Treatment allocation will be coded, and clinical photographs and outcome measurements will be evaluated without identification of the intervention received on each side.
Participants will receive the Mesolipo® protocol on one side of the body for the treatment of localized adiposity. The intervention consists of subcutaneous administration of the Mesolipo® formulation according to the standardized study protocol.
Participants will receive the comparator intervention on the contralateral side of the body. The comparator consists of the control formulation administered using the same injection technique and treatment schedule as the experimental intervention.
Belo Horizonte, Minas Gerais 30493-240, Brazil
Adebrelimab Combined With SOX Regimen in Preoperative Neoadjuvant Transformation Therapy for Locally Advanced Gastric Adenocarcinoma
Evaluating the Impact of GLP-1 Receptor Agonists With Total Neoadjuvant Therapy in Rectal Cancer
Efficacy and Safety of Neoadjuvant Sintilimab Plus FLOT Versus Sintilimab Plus SOX Phase II Clinical Trial for Patients With Locally Advanced Gastric Cancer
Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer
Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma
The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
New Adjuvant Treatment of Locally Advanced Resectable Gastric Cancer With Carelizumab and XELOX